Coherus Biosciences Stock Probability of Future Stock Price Finishing Over 1.04
CHRS Stock | USD 1.71 0.34 24.82% |
Coherus |
Coherus BioSciences Target Price Odds to finish over 1.04
The tendency of Coherus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current Price | Horizon | Target Price | Odds to stay above $ 1.04 in 90 days |
1.71 | 90 days | 1.04 | about 44.58 |
Based on a normal probability distribution, the odds of Coherus BioSciences to stay above $ 1.04 in 90 days from now is about 44.58 (This Coherus BioSciences probability density function shows the probability of Coherus Stock to fall within a particular range of prices over 90 days) . Probability of Coherus BioSciences price to stay between $ 1.04 and its current price of $1.71 at the end of the 90-day period is about 44.5 .
Given the investment horizon of 90 days Coherus BioSciences has a beta of 0.42 suggesting as returns on the market go up, Coherus BioSciences average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Coherus BioSciences will be expected to be much smaller as well. Additionally Coherus BioSciences has an alpha of 0.5079, implying that it can generate a 0.51 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Coherus BioSciences Price Density |
Price |
Predictive Modules for Coherus BioSciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Coherus BioSciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Coherus BioSciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Coherus BioSciences is not an exception. The market had few large corrections towards the Coherus BioSciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Coherus BioSciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Coherus BioSciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.51 | |
β | Beta against Dow Jones | 0.42 | |
σ | Overall volatility | 0.22 | |
Ir | Information ratio | 0.06 |
Coherus BioSciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Coherus BioSciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Coherus BioSciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.Coherus BioSciences is way too risky over 90 days horizon | |
Coherus BioSciences may become a speculative penny stock | |
Coherus BioSciences appears to be risky and price may revert if volatility continues | |
Coherus BioSciences has high likelihood to experience some financial distress in the next 2 years | |
The company reported the previous year's revenue of 257.24 M. Net Loss for the year was (237.89 M) with loss before overhead, payroll, taxes, and interest of (58.4 M). | |
Coherus BioSciences currently holds about 275.48 M in cash with (174.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.54, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Coherus BioSciences has a frail financial position based on the latest SEC disclosures | |
Roughly 70.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from bizjournals.com: Redwood City-based Coherus stock surges after major drug sale |
Coherus BioSciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Coherus Stock often depends not only on the future outlook of the current and potential Coherus BioSciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Coherus BioSciences' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding | 94.2 M | |
Cash And Short Term Investments | 117.7 M |
Coherus BioSciences Technical Analysis
Coherus BioSciences' future price can be derived by breaking down and analyzing its technical indicators over time. Coherus Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Coherus BioSciences. In general, you should focus on analyzing Coherus Stock price patterns and their correlations with different microeconomic environments and drivers.
Coherus BioSciences Predictive Forecast Models
Coherus BioSciences' time-series forecasting models is one of many Coherus BioSciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Coherus BioSciences' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Coherus BioSciences
Checking the ongoing alerts about Coherus BioSciences for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Coherus BioSciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Coherus BioSciences is way too risky over 90 days horizon | |
Coherus BioSciences may become a speculative penny stock | |
Coherus BioSciences appears to be risky and price may revert if volatility continues | |
Coherus BioSciences has high likelihood to experience some financial distress in the next 2 years | |
The company reported the previous year's revenue of 257.24 M. Net Loss for the year was (237.89 M) with loss before overhead, payroll, taxes, and interest of (58.4 M). | |
Coherus BioSciences currently holds about 275.48 M in cash with (174.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.54, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Coherus BioSciences has a frail financial position based on the latest SEC disclosures | |
Roughly 70.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from bizjournals.com: Redwood City-based Coherus stock surges after major drug sale |
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.